Abstracts Archive - Page 2457 of 2607 - ACR Meeting Abstracts

Abstract Number: 2215 • 2012 ACR/ARHP Annual Meeting
Assessment of Vascular Age in Psoriatic Arthritis Patients
Jl Rosales-Alexander¹, César Magro Checa¹, Juan Salvatierra¹, Jesús Cantero Hinojosa² and Enrique Raya Álvarez¹, ¹Rheumatology, University Hospital San Cecilio, Granada, Spain, ²Internal Medicine, University Hospital San Cecilio, Granada, Spain
Background/Purpose: The European League Against Rheumatism (EULAR) recommends cardiovascular risk (CV) assessment using the systematic coronary risk evaluation (SCORE) chart in inflammatory arthritis patients. However,…
Abstract Number: 2216 • 2012 ACR/ARHP Annual Meeting
Cardiovascular Risk Assessment in Spondyloarthritis Using the Score Chart and Reclassification by Presence of Plaques On Ultrasonography
Jl Rosales-Alexander¹, Juan Salvatierra¹, César Magro Checa¹, Jesús Cantero Hinojosa² and Enrique Raya Álvarez¹, ¹Rheumatology, University Hospital San Cecilio, Granada, Spain, ²Internal Medicine, University Hospital San Cecilio, Granada, Spain
Background/Purpose: Increased cardiovascular (CV) risk have been described in patients with rheumatic diseases including spondyloarthritis (SpA). Besides traditional CV risk factors, disease specific factors have…
Abstract Number: 2217 • 2012 ACR/ARHP Annual Meeting
Even After Pretreatment with up to Three Biologics, Anti-TNFs Shows Effectiveness in Active Psoriatic Arthritis Patients
Frank Behrens¹, Michaela Koehm¹, Diamant Thaci², Brigitte Krummel-Lorenz³, Gerd Greger⁴, Bianca Wittig⁴ and Harald Burkhardt⁵, ¹CIRI/Div. Rheumatology, J.W. Goethe-University, Frankfurt/Main, Germany, ²Klinik für Dermatologie, Venerologie und Allergologie, J.W. Goethe University, Frankfurt/Main, Germany, ³CIRI/Endokrinologikum, Frankfurt/Main, Germany, ⁴Abbott GmbH & Co KG, Wiesbaden, Germany, ⁵CIRI /Div. of Rheumatology, Goethe-University, Frankfurt/Main, Frankfurt/Main, Germany
Background/Purpose: For the treatment of patients with psoriatic arthritis (PsA) only antiTNF biologics are licensed. Therefore, failures to anti-TNF are often switched to a different…
Abstract Number: 2218 • 2012 ACR/ARHP Annual Meeting
5 Year Safety, Efficacy, and Radiographic Data in Patients with Active Psoriatic Arthritis Treated with Golimumab: Results From the Long-Term Extension of a Randomized, Placebo-Controlled Study
Arthur Kavanaugh¹, Desiree M. van der Heijde², Iain B. McInnes³, Philip J. Mease⁴, Gerald G. Krueger⁵, Dafna D. Gladman⁶, Yiying Zhou⁷, J. D. Lu⁸, Zhenhua Xu⁹, Lenore Noonan¹⁰ and Anna Beutler⁹, ¹UCSD School of Medicine, La Jolla, CA, ²Dept of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³University of Glasgow, Glasgow, United Kingdom, ⁴Rheumatology Research, Swedish Medical Center, Seattle, WA, ⁵School of Medicine, University of Utah, Salt Lake City, UT, ⁶Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ⁷Biostatistics, Janssen Research & Development, LLC., Spring House, PA, ⁸Janssen Research & Development, LLC, Spring House, PA, ⁹Janssen Research & Development, LLC., Spring House, PA, ¹⁰Immunology, Janssen Research & Development, LLC., Spring House, PA
5 year safety, efficacy, and radiographic data in patients with active psoriatic arthritis treated with golimumab: Results from the long-term extension of the randomized, placebo-controlled,…
Abstract Number: 2219 • 2012 ACR/ARHP Annual Meeting
Patients with Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis Show Similar Response Rates After One Year of Treatment with Etanercept – results of the Esther Trial
In-Ho Song¹, Kay-Geert A. Hermann², Hildrun Haibel¹, Christian Althoff³, Denis Poddubnyy⁴, Joachim Listing⁵, Anja Weiß⁶, Ekkehard Lange⁷, Bruce Freundlich⁸, Martin Rudwaleit⁹ and Joachim Sieper¹⁰, ¹Medical Department I, Rheumatology, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany, ²Radiology, Charité Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany, ³Radiology, Charite Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany, ⁴Charité Universitätsmedizin Berlin, Berlin, Germany, ⁵German Rheumatism Research Center, Berlin, Germany, ⁶German Rheumatism Research Centre, Berlin, Germany, ⁷BU Specialty Care, Pfizer Pharma AG, Berlin, Germany, ⁸University of Pennsylvania, Philadelphia, PA, ⁹Endokrinologikum Berlin, Berlin, Germany, ¹⁰Medical Department I, Rheumatology, Charité Universitätesmedizin Berlin, Berlin, Germany
Background/Purpose: In patients with early axial spondyloarthritis (SpA) with a disease duration < 5 years we assessed whether there is a difference to etanercept (ETA)…
Abstract Number: 2220 • 2012 ACR/ARHP Annual Meeting
Development of the Pulsar (Program to Understand the Longterm Outcomes in Spondyloarthritis) Registry
Andreas M. Reimold¹, Liron Caplan², Daniel O. Clegg³, Gail S. Kerr⁴, Elizabeth Chang⁵, Lisa A. Davis⁶, Prashant Kaushik⁷, Vikas Majithia⁸, J. Steuart Richards⁹, Joel D. Taurog¹⁰ and Jessica Walsh¹¹, ¹Rheumatology, Dallas VA and University of Texas Southwestern, Dallas, TX, ²Div of Rheumatology, Denver VA and Univ of Colorado School of Medicine, Aurora, CO, ³Division of Rheumatology, George E. Wahlen Veteran Affairs Medical Center, Salt Lake City, UT, ⁴Rheumatology, Washington DC VAMC, Georgetown and Howard University, Washington, DC, ⁵Phoenix VAHCS, Phoenix, AZ, ⁶Division of Rheumatology, Denver Health and Hospital Authority, Denver, CO, ⁷Department of Medicine, Sratton VAMC, Albany, NY, ⁸Div of Rheumatology, University of Mississippi Medical Center, Jackson, MS, ⁹Rheumatology, Washington DC VA and Georgetown University, Washington, DC, ¹⁰Internal Medicine, Rheumatic Diseases Division, UT Southwestern Medical Center, Dallas, TX, ¹¹Rheumatology, University of Utah Hospital, Salt Lake City, UT
Background/Purpose: The spondyloarthritides are a group of conditions characterized by inflammation in the axial skeleton or peripheral joints. The arthritis may present as the primary…
Abstract Number: 2221 • 2012 ACR/ARHP Annual Meeting
Major Adverse Cardiovascular Events Are More Common in Rheumatoid Arthritis Than in Psoriatic Arthritis and Are Associated with Different Risk Factors
Allen P. Anandarajah¹, Katherine C. Saunders², George W. Reed³, Alina U. Onofrei³, Jeffrey D. Greenberg⁴ and Christopher T. Ritchlin⁵, ¹Dept of Rheumatology, Univ of Rochester Medical Ctr, Rochester, NY, ²Corrona, LLC., Southborough, MA, ³University of Massachusetts Medical School, Worcester, MA, ⁴NYU Hospital for Joint Diseases, New York, NY, ⁵Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY
Background/Purpose: Rheumatoid Arthritis (RA) is associated with increased cardiovascular mortality and morbidity rates. Similarly several studies have reported an increased risk for cardiovascular events in…
Abstract Number: 2182 • 2012 ACR/ARHP Annual Meeting
Prevalence of Fibromyalgia Is Increased in Primary Sjögren’s Syndrome Compared with SLE and Associated with Depression and Severe Vitamin D Deficiency
Byoong Yong Choi¹, Hye Jin Oh², Jun Won Park³, Bon Seung Ku², Sung Hae Chang², Eun Young Lee², Eun Bong Lee² and Yeong Wook Song⁴, ¹Division of Rheumatology, Department of Internal Medicine, Seoul Medical Center, Seoul, South Korea, Seoul, South Korea, ²Internal Medicine, Seoul National University Hospital, Seoul, South Korea, ³Division of Rheumatology, Department of Internal Medicine, Rheumatology, Seoul National University, Seoul, South Korea, ⁴Internal Medicine,, Seoul National University Hospital, Seoul, South Korea
Background/Purpose: Although clinical features of primary Sjögren's syndrome (pSS) overlap with those of fibromyalgia (FM), the relationship between FM and pSS has remained unclear. Furthermore,…
Abstract Number: 2183 • 2012 ACR/ARHP Annual Meeting
Common Features in Lymphoproliferative Complications in the Course of Primary Sjögren’s Syndrome: Results From a Multicenter Cohort of 1170 Patients
Luca Quartuccio¹, Chiara Baldini², Roberta Priori³, Elena Bartoloni Bocci⁴, Francesco Carubbi⁵, Miriam Isola⁶, Marta Maset⁷, Sara Salvin⁷, Nicoletta Luciano², Giovanna Picarelli⁸, Alessia Alunno⁹, Roberto Giacomelli¹⁰, Roberto Gerli¹¹, Guido Valesini¹², Stefano Bombardieri¹³ and Salvatore De Vita¹, ¹Rheumatology, DSMB, University Hospital Santa Maria della Misericordia, Udine, Italy, ²University of Pisa, Rheumatology Unit, Pisa, Italy, ³Department of Internal Medicine and Medical Specialties, Sapienza University, Rome, Italy, ⁴Rheumatology Unit, Department of Clinical & Experimental Medicine, University of Perugia, Perugia, Italy, ⁵Rheumatology Clinic, University of L'Aquila, L'Aquila, Italy, ⁶Institute of Statistics, University of Udine, Udine, Italy, ⁷Rheumatology Clinic, DSMB, University of Udine, Italy, Udine, Italy, ⁸Rheumatology Unit, Sapienza University of Rome, Rome, Italy, ⁹Clinical and Experimental Medicine, Rheumatology Unit, University of Perugia, Perugia, Italy, ¹⁰Rheumatology Unit, University of Aquila, L'Aquila, Italy, ¹¹Rheumatology Unit, University of Perugia, Perugia, Italy, ¹²Clinica e Terapia Medica, Sapienza, Universita di Roma, Rome, Italy, ¹³Department of Clinical and Experimental Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy
Background/Purpose: To describe the prevalence of lymphoproliferative complications (defined as B-cell lymphoma or definite conditions predisposing to lymphoma, i.e, cryoglobulinemic vasculitis (CV) and major salivary…
Abstract Number: 2184 • 2012 ACR/ARHP Annual Meeting
Pregnancy and Fetal Outcome in Patients with an Established Diagnosis of Primary Sjögren’s Syndrome.
Roberta Priori¹, Angelica Gattamelata², Mariagrazia Modesti³, Serena Colafrancesco³, Marta Maset⁴, Luca Quartuccio⁴, Salvatore De Vita⁵, Elena Bartoloni Bocci⁶, Alessia Alunno⁷, Roberto Gerli⁶, Francesca Strigini⁸, Chiara Baldini⁹, Chiari Tani⁹, Marta Mosca⁹, Stefano Bombardieri⁹ and Guido Valesini³, ¹Department of Internal Medicine and Medical Specialties, Sapienza University, Rome, Italy, ²Sapienza University of Rome, Rome, Italy, ³Rheumatology Unit, Sapienza University of Rome, Rome, Italy, ⁴Rheumatology Clinic, DSMB, University of Udine, Udine, Italy, ⁵Rheumatology, DSMB, University Hospital Santa Maria della Misericordia, Udine, Italy, ⁶Rheumatology Unit, Department of Clinical & Experimental Medicine, University of Perugia, Perugia, Italy, ⁷Clinical and Experimental Medicine, Rheumatology Unit, University of Perugia, Perugia, Italy, ⁸Internal Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy, ⁹Rheumatology Unit, University of Pisa, Pisa, Italy
Background/Purpose: To investigate pregnancy and fetal outcome in patients with an established diagnosis of primary Sjögren’s syndrome (pSS) Methods: The clinical charts of 1075 women with…
Abstract Number: 2185 • 2012 ACR/ARHP Annual Meeting
Prevalence of Severe Extra-Glandular Manifestations in a Large Cohort of Patients with Primary Sjögren’s Syndrome
Chiara Baldini¹, Pasquale Pepe², Luca Quartuccio³, Roberta Priori⁴, Elena Bartoloni Bocci⁵, Alessia Alunno⁶, Serena Colafrancesco⁷, Angelica Gattamelata⁸, Marta Maset⁹, Mariagrazia Modesti⁷, Antonio Tavoni¹⁰, Salvatore De Vita⁹, Roberto Gerli⁵, Guido Valesini⁷ and Stefano Bombardieri¹¹, ¹University of Pisa, Rheumatology Unit, Pisa, Italy, ²Department of Internal Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy, ³Rheumatology, DSMB, University Hospital Santa Maria della Misericordia, Udine, Italy, ⁴Department of Internal Medicine and Medical Specialties, Sapienza University, Rome, Italy, ⁵Rheumatology Unit, Department of Clinical & Experimental Medicine, University of Perugia, Perugia, Italy, ⁶Clinical and Experimental Medicine, Rheumatology Unit, University of Perugia, Perugia, Italy, ⁷Rheumatology Unit, Sapienza University of Rome, Rome, Italy, ⁸Sapienza University of Rome, Rome, Italy, ⁹Rheumatology Clinic, DSMB, University of Udine, Italy, Udine, Italy, ¹⁰University of Pisa, Immunoallergology Unit, Pisa, Italy, ¹¹Department of Clinical and Experimental Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy
Background/Purpose: i) to describe the clinico- serological features of a cohort of 1115 patients with primary Sjögren’s syndrome (pSS); ii) to assess the prevalence of systemic extra-glandular…
Abstract Number: 2186 • 2012 ACR/ARHP Annual Meeting
Ultrasonography of Major Salivary Glands in Primary Sjögren’s syndrome
Malin V. Jonsson¹, Daniel Hammenfors², Johan G. Brun² and Roland Jonsson³, ¹Department of Clinical Dentistry - Section for Oral and Maxillofacial Radiology, University of Bergen, Bergen, Norway, ²Department of Rheumatology, Haukeland University Hospital, Bergen, Norway, ³Broegelmann Research Laboratory, the Gade Institute, University of Bergen, Bergen, Norway
Background/Purpose: Minor salivary gland biopsy is part of the diagnostic process for primary Sjögren’s syndrome (pSS), but is not suitable for repeated follow-up. Ultrasound (US)…
Abstract Number: 2187 • 2012 ACR/ARHP Annual Meeting
Safety of Minor Labial Salivary Gland Biopsy
ŽIga Rotar, Alojzija Hočevar, NatašA. Gašperšič, Branka Hostnik, Anita Antolić and Matija Tomšič, Department of Rheumatology, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia
Background/Purpose: Histopathological analysis of minor salivary glands is a part of the latest classification criteria for SS proposed by the American-European Consensus Group (AECG), and…
Abstract Number: 2188 • 2012 ACR/ARHP Annual Meeting
How to Better Define Inclusion Criteria in a Large Controlled Trial in Primary Sjogren Syndrome ?
Valerie Devauchelle-Pensec¹, Xavier Mariette², Jacques-Eric Gottenberg³, Raphaèle Seror⁴, Anne-Laure Fauchais⁵, Olivier Vittecoq⁶, Véronique Le Guern⁷, Jacques Morel⁸, JJ Dubost⁹, Philippe Dieude¹⁰, Eric Hachulla¹¹, Pierre yves Hatron¹², C. Larroche¹³, Aleth Perdriger¹⁴, Xavier Puechal¹⁵, Damien Sene Sr.¹⁶, Stephanie Rist¹⁷ and Alain Saraux¹⁸, ¹Department of rheumatology and unit of immunology EA2216, Brest Occidentale university, Brest, France, ²Rheumatology, Université Paris-Sud, Le Kremlin Bicetre, France, ³Rheumatology, Strasbourg University Hospital, Strasbourg, France, ⁴Rheumatology, Bicetre university hospital, LE Kremlin-Bicetre, France, ⁵Department of Internal Medicine A, Dupuytren Hospital, Limoges University Hospital, Limoges, France, ⁶Rheumatology, Rouen University Hospital & Inserm905, University of Rouen, Rouen Cedex, France, ⁷Department of Internal Medicine, Cochin Hospital, Paris, France, ⁸Dpartment of Rheumatology, Lapeyronie Hospital, Montpellier, France, ⁹Rheumatology, CHU CLERMONT-FERRAND, Clermont-Ferrand, France, ¹⁰Rheumatology, Rheumatology departement & INSERM U699, Paris Diderot university, APHP, Bichat hospital, Paris, France, ¹¹Department of Internal Medicine, Claude Huriez University Hospital, Lille, France, ¹²Department of Internal Medicine, Hôpital Claude Huriez, Université Lille II, Lille, France, Paris, France, ¹³Hospital University Bobigny, bobigny, France, ¹⁴Rheumatology, Hôpital Sud, Rennes, France, ¹⁵Internal Medicine, Hôpital Cochin, Paris, France, ¹⁶Department of Internal Medicine; 5 P3S post-genomic plateform, Groupe Hospitalier Pitié-Salpétrière, Université Pierre et Marie Curie, Paris, France, ¹⁷Rheumatology, Orleans Hospital, Orleans, France, ¹⁸Department of rheumatology and unit of immunology (EA 2216), Université Brest Occidentale, Brest, France
Background/Purpose: The subsets of primary Sjögren's syndrome (pSS) patients justifying biological therapy (BT) remain a matter of debate. Our goal was [1] to describe which…
Abstract Number: 2189 • 2012 ACR/ARHP Annual Meeting
Efficacy of Belimumab On Non-Malignant Parotid Swelling and Systemic Manifestations of Sjögren’s Syndrome: Results of the Beliss Study
Salvatore De Vita¹, Raphaèle Seror², Luca Quartuccio³, Frederic Desmoulins⁴, Sara Salvin⁵, Gabriel Baron⁶, Martina Fabris⁷, Philippe Ravaud⁸, Miriam Isola⁹ and Xavier Mariette¹⁰, ¹Rheumatology, DSMB, University Hospital Santa Maria della Misericordia, Udine, Italy, ²Rheumatology, Université Paris-Sud, Le Kremlin Bicêtre, LE Kremlin-Bicetre, France, ³Rheumatology Clinic, DSMB, University of Udine, Udine, Italy, ⁴Rheumatology, Université Paris-Sud, Le Kremlin Bicêtre, Le Kremlin Bicetre, France, ⁵Rheumatology Clinic, DSMB, University of Udine,, Udine, Italy, ⁶Epidemiology & Clinical Research, Groupe Hospitalier Bichat-Claude Bernard, Paris, France, ⁷Institute of Clinical Pathology, Udine, Italy, ⁸Epidemiology, Université Paris-Descartes, Paris, Paris, France, ⁹Institute of Statistics, DSMB, University of Udine, Udine, Italy, ¹⁰Rheumatology, Université Paris-Sud, Le Kremlin Bicetre, France
Background/Purpose: to report the effects of anti-BAFF/BLyS antibody belimumab (BEL) on the different ogan manifestations of primary Sjögren’s syndrome (pSS), by evaluating the ESSDAI score…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].